J&J MedTech's Next Growth Phase
Johnson & Johnson MedTech CEO Tim Schmid announced the company's entry into its next growth phase, focusing on surgical robotics, cardiovascular technologies, and portfolio management.
According to Schmid, J&J MedTech is "leaning in" to high-growth areas of cardiovascular, surgery, and vision.
The company will separate its orthopedics business into a standalone company. J&J MedTech generated $8.4 billion in revenue last quarter, growing 5.6% year-over-year.
- Key areas of focus: surgical robotics, cardiovascular technologies, and vision
- Revenue growth: 5.6% year-over-year, led by cardiovascular technologies and wound closure
Author's summary: J&J MedTech enters next growth phase with focus on robotics and portfolio management.